Welcome Message

Welcome to the 12th International Conference on Geriatric Cardiology, Cardiovascular Diseases, and Palliative Care
October 22-23, 2025 | Paris, France

It is with great pleasure that we welcome you to this pivotal gathering of healthcare professionals, researchers, and advocates dedicated to advancing the field of geriatric cardiology. Over the next two days, we come together with a shared commitment: to improve cardiovascular health and enhance the quality of life for older adults worldwide.

As we navigate one of the most profound demographic shifts of our time, the aging population presents both challenges and opportunities in cardiovascular care. This conference provides a vital platform to explore innovative solutions, share cutting-edge research, and foster meaningful collaborations that address these unique needs.

Our dynamic program includes keynote addresses from esteemed global experts, groundbreaking research presentations, interactive workshops, and opportunities to connect with peers from around the world. Whether you are a seasoned cardiologist, a geriatric care specialist, a researcher, or a healthcare policy advocate, your presence and insights are instrumental in shaping the future of geriatric cardiology.

As we engage in this collective journey of discovery and innovation, let us keep in mind the individuals who inspire our work—the older adults who rely on us for compassionate, evidence-based care. Their well-being remains at the heart of our mission, driving us to push the boundaries of what is possible.

We are honored by your participation in this momentous event and eagerly anticipate the ideas, inspiration, and progress that will emerge from our shared efforts.

Welcome, and together, let’s make a lasting impact.

Sessions & Tracks

Palliative Care Across Specialties

Oncology and Geriatrics
Palliative care in oncology focuses on alleviating symptoms, enhancing quality of life, and addressing the emotional and psychosocial challenges faced by cancer patients. In geriatrics, it aims to meet the unique needs of older adults, balancing chronic disease management with comfort-focused interventions.

Cardiology, Pediatrics, and Neurology
In cardiology, palliative care supports patients with advanced heart diseases, offering relief from symptoms like breathlessness and fatigue while addressing end-of-life planning. Pediatric palliative care provides holistic support for children with life-limiting conditions and their families. In neurology, it plays a crucial role in managing conditions like ALS, Parkinson's, and advanced dementia, ensuring dignity and comfort.

Critical Care and Specialized Areas
Critical care palliative services integrate symptom management with decision-making support for critically ill patients. Hematology, pulmonology, nephrology, and gastroenterology utilize palliative care to address the complexities of organ-specific diseases, from managing anemia and respiratory distress to alleviating renal failure symptoms and gastrointestinal discomfort, ensuring patient-centered care across all stages of illness.

Geroscience and Cardiovascular Health: Emerging studies emphasize the role of geroscience, which targets the biological mechanisms of aging, such as cellular senescence and mitochondrial dysfunction. These interventions aim to prevent or delay the onset of age-related CVD and associated frailty. 

Percutaneous Coronary Interventions (PCI) and Surgery: For older adults, PCI continues to be a vital treatment for acute coronary syndromes, showing lower in-hospital mortality rates compared to medical therapy. However, research also indicates that in high-risk cases, coronary artery bypass grafting (CABG) may offer better long-term outcomes. 

Tailoring Treatments to Age and Frailty: Research highlights the complexities of managing polypharmacy, bleeding risks, and cognitive concerns in elderly patients undergoing cardiovascular procedures. 

The Impact of Kinlessness on Older Adults with Advanced Heart Failure

Recent studies highlight the significant challenges faced by older adults with advanced heart failure (HF) who lack traditional kin networks (spouses or children). Kinlessness, a growing phenomenon, has been linked to poorer access to advanced treatments like left ventricular assist devices (LVADs) or heart transplants. Social isolation also correlates with higher rates of institutionalization and unmet care needs. Research underscores disparities in care: kinless patients are often under-referred for advanced therapies and face barriers in end-of-life care, with fewer dying in hospice settings compared to those with kin. These findings stress the need for targeted social support interventions to address these inequities

Revascularization in Frail Patients With Acute Coronary Syndrome (ACS)

Recent studies highlight the importance of tailoring treatment strategies for frail patients presenting with ACS. Revascularization, involving percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), has shown both short- and long-term cardiovascular (CV) benefits in this population.

A large-scale retrospective study using the UK’s Hospital Episode Statistics database examined over 565,000 ACS patients, categorizing them by frailty risk (low, intermediate, and high). Findings revealed that frail patients, often underrepresented in clinical trials, experienced significant reductions in CV mortality following revascularization, particularly in the first year after ACS. Notably, high and intermediate frailty patients saw greater immediate mortality benefits compared to low-frailty patients.

Older Patients With Non–ST-Segment Elevation Myocardial Infarction Randomized Interventional Treatment

The SENIOR-RITA trial, the largest randomized controlled study to date focusing on older patients with Non–ST-Segment Elevation Myocardial Infarction (NSTEMI), evaluated the outcomes of invasive versus conservative strategies in this population. It specifically included elderly individuals aged 75 and older, many of whom were frail or had multiple comorbidities.

Key findings include:

1. Primary Endpoint: There was no significant difference in the composite outcome of cardiovascular death or non-fatal myocardial infarction (MI) between the invasive strategy group (25.6%) and the conservative strategy group (26.3%). This result suggests that routine invasive treatment may not provide superior cardiovascular protection over conservative management.
2. Secondary Outcomes: The invasive group experienced fewer non-fatal MIs (11.7% vs. 15.0%) and fewer subsequent revascularizations compared to the conservative group. However, bleeding events were slightly higher in the invasive group, underscoring the importance of weighing risks and benefits.
3. Safety and Applicability: Coronary revascularization using radial artery access was deemed relatively safe for older adults, challenging concerns about procedural risks in this demographic.

The trial emphasized the necessity of individualized treatment approaches, considering factors like frailty and cognitive status, rather than defaulting to invasive methods. Its findings contribute valuable insights to the ongoing debate about optimal care strategies for older NSTEMI patients, but also highlight gaps, such as the need for data on patients with higher clinical complexity

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The EMPEROR-Preserved trial evaluated the efficacy of empagliflozin, an SGLT2 inhibitor, in patients with chronic heart failure with preserved ejection fraction (HFpEF). This international, multicenter study included 5,998 participants and was conducted across 622 centers in 23 countries. Patients were randomized to receive either empagliflozin (10 mg daily) or a placebo, alongside standard care, over a median follow-up period of 26 months.

Key findings from the trial include a 21% reduction in the combined risk of cardiovascular death or hospitalization for heart failure among those treated with empagliflozin compared to placebo. The reduction in total heart failure hospitalizations was even more pronounced at 27%. 

AF Screening With a 14-Day ECG Monitor

Recent studies highlight the use of 14-day ECG monitoring for atrial fibrillation (AF) screening in older adults. One such trial, the GUARD-AF study, focused on individuals aged 70 and older without prior AF diagnosis. The use of a continuous patch-based ECG monitor significantly increased AF detection rates by over 50% compared to usual care. 

Cardiometabolic Health: An Integrative Approach to Prevention and Management

Cardiometabolic health encompasses the interplay between cardiovascular diseases (CVDs) and metabolic disorders, including diabetes, obesity, hypertension, and dyslipidemia. This multifaceted domain addresses the underlying mechanisms linking metabolic imbalances to cardiovascular outcomes, emphasizing prevention, early detection, and personalized treatment strategies.

Key Components and Risk Factors
Cardiometabolic disorders are driven by factors such as insulin resistance, chronic inflammation, endothelial dysfunction, and oxidative stress. Lifestyle behaviors, including poor diet, physical inactivity, and chronic stress, alongside genetic predisposition, significantly contribute to the development of cardiometabolic syndromes. These conditions are strongly associated with obesity, particularly visceral fat, and abnormal lipid profiles.

Clinical Implications
Effective management requires a multidimensional approach. Weight reduction, dietary improvements like the adoption of the Mediterranean or DASH diets, regular exercise, and smoking cessation play pivotal roles in mitigating risk. Pharmacological interventions, including statins, GLP-1 receptor agonists, and SGLT2 inhibitors, have proven effective in managing dyslipidemia, hyperglycemia, and heart failure risks.

Global Burden and Innovations
Cardiometabolic disorders are leading causes of morbidity and mortality worldwide, significantly straining healthcare systems. Innovations in digital health tools, such as wearable technologies and telemedicine, enable continuous monitoring and personalized feedback, improving patient adherence to therapeutic goals.

Future Directions
Emerging fields, like precision medicine and metabolic imaging, promise to refine cardiometabolic risk stratification and intervention. Public health initiatives focusing on education, equitable healthcare access, and environmental changes are critical to addressing the global burden of cardiometabolic diseases comprehensively.

By integrating clinical care, lifestyle modification, and community engagement, cardiometabolic health initiatives aim to reduce disease prevalence and improve population-level cardiovascular and metabolic outcomes.

Cardio-oncology: Bridging Cancer Care and Cardiovascular Health

Cardio-oncology is an emerging medical field that focuses on the intersection of cardiovascular disease and cancer, particularly the cardiovascular effects of cancer treatments. Cancer therapies, such as chemotherapy, radiation, and targeted therapies, can cause significant damage to the heart and vasculature, leading to complications like cardiomyopathy, heart failure, arrhythmias, and vascular disease. The growing number of cancer survivors highlights the importance of monitoring and managing long-term cardiovascular risks in these patients.

The main goal of cardio-oncology is to identify patients at risk for cardiovascular complications due to cancer treatments and develop preventive and therapeutic strategies. Early screening, including echocardiograms and biomarkers, is vital for detecting early signs of heart damage. Cardio-oncology specialists collaborate closely with oncologists to tailor cancer therapies that minimize cardiovascular risk while effectively treating the cancer.

With the rise of more effective and longer-lasting cancer treatments, cardio-oncology is increasingly essential in improving the quality of life and longevity of cancer survivors. 

Cerebrovascular Disease & Stroke

Cerebrovascular disease refers to a range of conditions that affect the blood vessels in the brain, leading to stroke and transient ischemic attacks (TIAs). Stroke remains a leading cause of disability and death worldwide, often caused by either a blockage (ischemic stroke) or bleeding (hemorrhagic stroke). Advances in prevention, such as lifestyle modifications and medical interventions, as well as improvements in acute stroke care, have contributed to better outcomes for many patients. 

Critical Care & Resuscitation
Critical care and resuscitation focus on the immediate treatment of patients with life-threatening conditions, such as cardiac arrest, severe trauma, and organ failure. In cardiovascular settings, resuscitation techniques, including CPR and defibrillation, are vital for saving lives. Advances in this area include improved protocols for post-cardiac arrest care, such as therapeutic hypothermia, and innovations in mechanical circulatory support devices. 

Congenital heart disease (CHD) refers to structural abnormalities of the heart that are present at birth. It can involve defects in the heart walls, valves, or blood vessels. Advances in early detection, prenatal screening, and surgical interventions have greatly improved survival rates for children born with CHD. Many individuals with CHD live into adulthood, requiring ongoing management for complications, such as arrhythmias and heart failure. The field continues to evolve with innovations in minimally invasive procedures, genetic testing, and lifelong care strategies

Coronary, peripheral, and structural interventions involve medical procedures aimed at correcting blockages, narrowing, or structural abnormalities in the heart and blood vessels. This includes coronary artery bypass grafting (CABG), angioplasty, stent placement, and endovascular procedures for peripheral artery disease. Structural interventions also include valve replacements and repairs for heart valve diseases. 

Gene & Tissue Regeneration
Genetics, omics, and tissue regeneration in cardiology represent cutting-edge areas of research aimed at understanding the genetic basis of cardiovascular diseases and using technology to repair or regenerate damaged tissues. Genomic studies are uncovering genetic mutations linked to heart disease, offering new avenues for personalized medicine. Advances in stem cell therapy and tissue engineering hold promise for repairing heart tissue damaged by infarction or other cardiovascular conditions. Omics technologies, including genomics, proteomics, and metabolomics, provide comprehensive insights into disease mechanisms, offering new targets for treatment .

Health Promotitive Cardiology
Health promotion and preventive cardiology focus on strategies to prevent cardiovascular diseases before they develop, rather than treating them once they occur. Lifestyle interventions, including diet, physical activity, and smoking cessation, play a critical role in reducing risk factors such as obesity, hypertension, and diabetes. Screening programs for early detection of risk factors, along with patient education, are central to preventive cardiology. Public health initiatives also promote the importance of cardiovascular health in all age groups, aiming to reduce the global burden of heart disease.

Heart Failure

Heart failure (HF) occurs when the heart cannot pump sufficient blood to meet the body's needs. Cardiomyopathies, diseases of the heart muscle, are a leading cause of heart failure. Treatment approaches for heart failure include medications, lifestyle changes, device therapy, and, in some cases, heart transplantation. Advances in pharmacotherapy, such as SGLT2 inhibitors and ARNI medications, have improved outcomes for heart failure patients. 

Hypertension

blood pressure, is a major risk factor for cardiovascular diseases, including stroke, heart failure, and kidney disease. Effective management of hypertension is essential to prevent these complications. Strategies include lifestyle modifications, such as weight loss, reduced salt intake, and regular exercise, along with pharmacological treatments like ACE inhibitors, calcium channel blockers, and diuretics. 

Techniques such as echocardiography, MRI, CT scans, and nuclear imaging allow for detailed visualization of the heart and blood vessels. These methods are essential for assessing conditions like coronary artery disease, heart failure, valve abnormalities, and congenital heart defects. Recent advancements in imaging technologies, including 3D imaging and artificial intelligence, are enhancing diagnostic accuracy, enabling earlier detection, and improving treatment planning.

Ischemic Heart Disease
(IHD), also known as coronary artery disease, occurs when the heart's blood supply is restricted due to the narrowing of coronary arteries. It is the leading cause of heart attacks and sudden cardiac death. Treatment includes lifestyle modifications, medications like statins and antiplatelets, and procedures such as angioplasty and coronary artery bypass surgery. Research is focused on improving early detection through biomarkers, developing new therapies to restore blood flow, and reducing the risk of recurrent cardiovascular events.

Outcomes & Quality
Cardiology focus on measuring the effectiveness of treatments and the overall improvement in patient health and life quality. Key indicators include survival rates, hospital readmission rates, and the ability of patients to manage their cardiovascular conditions. Quality improvement initiatives in cardiology aim to standardize care, reduce errors, and ensure patient-centered approaches. Data-driven efforts, including registries and patient-reported outcomes, are helping to enhance the quality of care and optimize health outcomes across populations.

Electrophysiology focuses on diagnosing and treating these arrhythmias through techniques like catheter ablation and pacemaker implantation. Advances in technology, including 3D mapping and robotic-assisted procedures, are improving the precision of treatments. Ongoing research aims to refine therapies and better understand the genetic and environmental factors contributing to arrhythmias.

Surgery

Cardiac surgery involve procedures to treat heart diseases, including coronary artery bypass grafting (CABG), valve replacements, and heart transplants. Surgical interventions are essential for patients with advanced cardiovascular conditions that cannot be managed with medications alone. Recent innovations, such as minimally invasive surgery and robotic-assisted procedures, have reduced recovery times and improved patient outcomes. Continued progress in surgical techniques and post-operative care is vital for improving the prognosis of cardiovascular patients

Valvular Heart Disease
Valvular refers to disorders affecting the heart's valves, including stenosis (narrowing) and regurgitation (leakage). These conditions can lead to heart failure and other complications if untreated. Treatment includes medication, lifestyle management, and surgery, including valve repair or replacement. The advent of transcatheter valve interventions has revolutionized the treatment of valvular heart disease, particularly in high-risk patients who may not be candidates for traditional surgery. Research continues to explore innovative valve therapies and outcomes for patients with these conditions.

Market Analysis

The global geriatric cardiology and cardiovascular diseases market is experiencing significant growth due to increasing aging populations, a higher prevalence of chronic diseases, and advancements in medical technology.

1. Geriatric Cardiology
   • Global Trends: The geriatric population (aged 65 and older) is projected to double by 2050, with cardiovascular diseases (CVD) remaining a leading cause of morbidity and mortality.
   • Market Drivers: Rising demand for specialized geriatric care, personalized medicine, and minimally invasive cardiovascular procedures.
2. Cardiovascular Diseases (CVD)
   • Market Size: Estimated to surpass $550 billion by 2030.
   • Key Areas: Heart failure management, arrhythmias, coronary artery disease, and advanced diagnostics using AI-powered imaging technologies.
3. Palliative Care
   • Global Demand: Increasing focus on improving the quality of life for patients with terminal CVD conditions.
   • Growth Areas: Integration of palliative care into cardiovascular management plans, especially in aging societies.
4. Regional Insights
   • North America: Dominates due to advanced healthcare infrastructure and high healthcare expenditure.
   • Europe: Significant growth driven by aging populations and governmental focus on chronic disease management.
   • Asia-Pacific: Rapid market expansion due to urbanization, lifestyle changes, and improved healthcare access.
5. Challenges
   • Workforce shortages in geriatrics and palliative care.
   • Economic barriers to accessing advanced treatments in low-income regions.
6. Future Outlook
   • Emphasis on early diagnosis and prevention through telemedicine, wearable devices, and remote patient monitoring.
   • Collaborative research and innovation in treatment strategies for aging populations

Here is a combination of a pie chart and a bar chart:

1. Pie Chart: Displays the approximate market share for North America, Europe, and Asia-Pacific in the Geriatric Cardiology and Cardiovascular Diseases market.
2. Bar Chart: Shows the projected growth of the cardiovascular market from 2020 to 2030.